RUMENSIN 200

Indications

• Chronic obstructive pulmonary disease (COPD)
• Asthma
• Occupational lung disease
• Allergic rhinitis
• Pulmonary fibrosis

Dosage

Children: Paediatric dosing for

Adults: Dosing for antidusting agents varies based on the specific medication prescribed. Refer to the relevant clinical guidelines or the BNF for specific dosing recommendations.

Mechanism of action

Antidusting agents may work through several mechanisms, including reducing inflammation in the airways, dilating bronchial passages, and facilitating the clearance of mucus. For example, inhaled corticosteroids act by inhibiting the inflammatory response in the airways, while bronchodilators relax the smooth muscle around the airways, leading to improved airflow. Mucolytics, on the other hand, thin mucus secretions, making them easier to expel from the respiratory tract.

Pharmacodynamics

The pharmacodynamics of antidusting agents vary depending on their class. Inhaled corticosteroids have a high affinity for glucocorticoid receptors, leading to decreased expression of inflammatory cytokines and a reduction in airway hyperresponsiveness. Bronchodilators, such as beta-agonists, stimulate beta-2 adrenergic receptors in bronchial smooth muscle, resulting in relaxation and dilation of the airways. Mucolytics break down the structure of mucus, enhancing mucociliary clearance.

Pharmacokinetics

Pharmacokinetics for antidusting agents differ based on the specific drug used. Inhaled formulations have localized effects in the lungs, with systemic absorption being minimal. The onset of action for bronchodilators can be rapid, with effects usually seen within minutes. Corticosteroids may take longer to show clinical benefits, often requiring days to weeks for full effect. Mucolytics are absorbed and distributed throughout the body, with renal excretion being a primary elimination route.

Pregnancy

Safety during pregnancy has not been established. Use only if potential benefit justifies potential risk to the fetus.

Breast-feeding

Caution is advised. The effects on a nursing infant are unknown.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Pain relief
• Anti-inflammatory treatment
• Antipyretic therapy
• Nutritional supplementation
• Electrolyte replacement
• Treatment of gastrointestinal disorders

Dosage

Children: Refer to specific product labeling or clinical guidelines for paediatric dosing, as this varies widely depending on the active ingredient and condition being treated.

Adults: Refer to specific product labeling or clinical guidelines for adult dosing, as this varies widely depending on the active ingredient and condition being treated.

Mechanism of action

The mechanism of action for granular formulations depends on the active pharmaceutical ingredient contained within the granules. Generally, these medications may work by various mechanisms such as inhibiting certain enzymes, blocking receptors, or modulating specific pathways involved in disease processes. For example, if the granules contain a medication that acts as an anti-inflammatory, it may inhibit the cyclooxygenase (COX) enzymes involved in the production of inflammatory mediators.

Pharmacodynamics

Pharmacodynamics describes how a drug affects the body. Granular medications can provide a rapid onset of action due to their surface area, which facilitates quicker dissolution and absorption. The effects vary depending on the active ingredient, which may influence various biological pathways, such as neurotransmitter modulation, receptor activation, or inhibition of certain cellular processes. The therapeutic effects are often dose-dependent and can be influenced by factors such as age, weight, and overall health.

Pharmacokinetics

The pharmacokinetics of granular formulations also vary based on the specific active ingredient. Generally, pharmacokinetic parameters include absorption, distribution, metabolism, and excretion (ADME). Granular medications typically exhibit faster absorption compared to solid dosage forms due to the larger surface area. Distribution will depend on factors like solubility and protein binding. Metabolism primarily occurs in the liver, while excretion can take place via the kidneys or bile, again depending on the nature of the active compound.

Pregnancy

Safety during pregnancy has not been established. Use only if clearly needed and potential benefits justify the risks.

Breast-feeding

Use with caution. Limited data available, and effects on the nursing infant are unknown.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Calcium deficiency
• Osteoporosis
• Osteomalacia
• Rickets
• Antacid for indigestion
• Heartburn

Dosage

Children: Refer to specific product guidelines for pediatric dosing, as recommendations depend on age, weight, and clinical indication.

Adults: Refer to specific product guidelines for dosing, as it may vary based on formulation and clinical condition.

Mechanism of action

Calcium carbonate acts as a source of calcium ions in the body. When ingested, it dissociates in the stomach to release calcium and carbonate ions. The calcium ions are then utilized in various physiological processes, including the formation of bones and teeth, muscle contraction, and neurotransmitter release. The carbonate ions can neutralize stomach acid, leading to symptomatic relief from acidity-related discomfort.

Pharmacodynamics

Calcium plays a vital role in numerous biochemical pathways. It is essential for the structural integrity of bones and teeth, involved in blood coagulation, and regulates muscle contractions and neurotransmitter release at synapses. The buffering action of carbonate helps maintain gastric pH, thereby providing relief from hyperacidity and associated symptoms.

Pharmacokinetics

Calcium carbonate is poorly soluble in water, which affects its absorption in the gastrointestinal tract. It is primarily absorbed in the small intestine, and its bioavailability is influenced by dietary factors, such as the presence of food. After absorption, calcium is distributed throughout the body, with about 99% stored in bones and teeth. The elimination of calcium occurs primarily through the kidneys, with some excretion in feces.

Adverse effects

• Constipation
• Nausea
• Vomiting
• Abdominal cramps
• Hypercalcemia
• Kidney stones

Interactions

• May interact with tetracycline antibiotics, reducing their absorption
• May affect the absorption of other medications due to changes in gastric pH

Precautions

• Use with caution in patients with renal impairment
• Monitor serum calcium levels in patients receiving high doses
• Assess for signs of hypercalcemia

Pregnancy

Limestone is generally considered safe during pregnancy but should only be used under medical supervision to avoid excessive calcium intake.

Breast-feeding

Calcium from limestone is excreted in breast milk, but it is generally safe for breastfeeding mothers to consume adequate amounts as part of a balanced diet.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Powder
• Tablet
• Chewable tablet
• Granules

Indications

• Inhibition of Wnt signaling in cancer therapy
• Treatment of coccidiosis in veterinary medicine
• Potential use in conditions related to aberrant Wnt signaling

Dosage

Children: Refer to specific guidelines or protocols as dosing can vary widely based on application and clinical context.

Adults: Refer to specific guidelines or protocols as dosing can vary widely based on application and clinical context.

Mechanism of action

Monensin acts as a potent inhibitor of the Wnt signaling pathway, which is crucial for embryonic development and tissue homeostasis. It inhibits the Wnt/beta-catenin signaling cascade by blocking the phosphorylation of the low-density lipoprotein receptor-related protein 6 (LRP6) and promoting its degradation, leading to reduced intracellular levels of beta-catenin. This results in decreased expression of Wnt target genes and reduced cell proliferation in human colorectal carcinoma cells.

Pharmacodynamics

Monensin affects cellular ion transport due to its ionophoric properties, facilitating the transport of sodium and other cations across cell membranes. This alteration in ion homeostasis can influence various cellular processes, including apoptosis and proliferation, particularly in cancer cells with deregulated Wnt signaling. The drug has been shown to suppress tumor progression in animal models without significant toxicity to normal tissues.

Pharmacokinetics

The pharmacokinetics of monensin are not well-documented in humans, as it is primarily utilized in veterinary medicine. However, it is known to be absorbed in the gastrointestinal tract and distributed throughout the body. The metabolic pathways and excretion routes remain largely undefined, necessitating further research to elucidate its pharmacokinetic profile in humans.

Pregnancy

There is insufficient data on the safety of monensin in pregnancy. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is unknown whether monensin is excreted in human breast milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Mechanism of action

The Wnt signaling pathway is required during embryonic development and for the maintenance of homeostasis in adult tissues. However, aberrant activation of the pathway is implicated in a number of human disorders, including cancer of the gastrointestinal tract, breast, liver, melanoma, and hematologic malignancies. In this study, we identified monensin, a polyether ionophore antibiotic, as a potent inhibitor of Wnt signaling. The inhibitory effect of monensin on the Wnt/beta-catenin signaling cascade was observed in mammalian cells stimulated with Wnt ligands, glycogen synthase kinase-3 inhibitors, and in cells transfected with beta-catenin expression constructs. Furthermore, monensin suppressed the Wnt-dependent tail fin regeneration in zebrafish and Wnt- or beta-catenin-induced formation of secondary body axis in Xenopus embryos. In Wnt3a-activated HEK293 cells, monensin blocked the phoshorylation of Wnt coreceptor low-density lipoprotein receptor related protein 6 and promoted its degradation. In human colorectal carcinoma cells displaying deregulated Wnt signaling, monensin reduced the intracellular levels of beta-catenin. The reduction attenuated the expression of Wnt signaling target genes such as cyclin D1 and SP5 and decreased the cell proliferation rate. In multiple intestinal neoplasia (Min) mice, daily administration of monensin suppressed progression of the intestinal tumors without any sign of toxicity on normal mucosa. Our data suggest monensin as a prospective anticancer drug for therapy of neoplasia with deregulated Wnt signaling. Preincubation of rat soleus muscle with 1 & 10 uM monensin for 2 hr increased the subsequent basal 2-deoxyglucose uptake by muscle 76 & 121% respectively. Under the same conditions, monensin decreased the insulin-stimulated (1 mU/mL) 2-deoxyglucose uptake by 29 & 37% respectively. The monensin-induced augmentation of basal 2-deoxyglucose uptake was inhibited 92% by cytochalasin B suggesting that the uptake is mediated by glucose transporters. Monensin did not incr the cellular accumulation of L-glucose in muscle indicating that it does not affect the cell membrane integrity. Neither the stimulatory effect of monensin on basal 2-deoxyglucose uptake nor the opposite, inhibitory action of monensin on the insulin-stimulated 2-deoxyglucose uptake were influenced by the removal of Ca2+ from the medium or by dantrolene, an inhibitor of Ca2+ release from the sarcoplasmic reticulum, suggesting that the actions of monensin are not mediated by calcium. Monensin had no effect on muscle ATP concn. The monensin-induced augmentation of basal 2-deoxyglucose uptake was neither associated with stimulation of muscle phosphatidylinositol 3-kinase activity nor inhibited by wortmannin, demonstrating that the incr in basal 2-deoxyglucose uptake is not mediated by activation of phosphatidylinositol 3-kinase. The inhibition of insulin-stimulated 2-deoxyglucose uptake by monensin was associated with a 31% decr in the abundance of insulin receptors in muscles, a 64% decr in the insulin-induced autophosphorylation of the insulin receptor beta-subunit, & a 44% reduction of the insulin-stimulated phosphatidylinositol 3-kinase activity. Addition of monensin into the phosphatidylinositol 3-kinase reaction had no effect on the activity of the enzyme, demonstrating that the inhibition in monensin-treated muscles is indirect & occurs upstream of phosphatidylinositol 3-kinase. It is concluded that monensin has a dual effect on 2-deoxyglucose uptake by skeletal muscle: it stimulates basal uptake but inhibits the insulin-stimulated uptake. The primary cause of the latter, inhibitory effect of monensin is at the level of the insulin receptor.